Tivorsan Pharmaceuticals to Present at Biotech Showcase™ 2015 on Monday, January 12

Providence, R.I., January 8, 2015 (BUSINESS WIRE) – Tivorsan Pharmaceuticals, Inc. today announced that Justin Fallon, PhD – Corporate Director, Founding Scientist and Brown University Professor – will present at next week’s Biotech Showcase™2015 in San Francisco, CA. Dr. Fallon will provide a company overview as well as the scientific rationale behind recombinant biglycan (TVN-102) as a disease-modifying treatment candidate for Duchenne Muscular Dystrophy and other progressive neuromuscular disorders.

Details of Tivorsan’s presentation are as follows:

Event:   Biotech Showcase™ 2015 Conference
Date:      Monday, January 12, 2015
Time:      9:45AM Pacific Standard Time
Location: Room Mission I; Parc 55 Wyndham San Francisco (Union Square)

The Biotech Showcase™ is an annual investor and partnering conference committed to providing private and public life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences.

Potential investors or partners interested in meeting with Tivorsan executives during the Biotech Showcase may contact President and Director, Dr. Joel B. Braunstein and Dr. Justin Fallon at info@tivorsan.com.

About Tivorsan Pharmaceuticals

Tivorsan Pharmaceuticals, Inc. is a protein therapeutics company pioneering a unique approach to treating serious neuromuscular disorders, including DMD, Becker Muscular Dystrophy (BMD), various congenital muscular dystrophies (CMD), and amyotrophic lateral sclerosis (ALS). The approach, using recombinant human biglycan, is based on 25 years of basic science work in the Fallon Laboratory at Brown University, Providence, RI. Tivorsan was formed by Dr. Fallon in collaboration with colleagues from Old Forge Holdings of Greenwich, CT and LifeTech Research, a Baltimore, MD-based technology research and development firm. Early support for the Tivorsan program originated, in part, from Federal sources, as well as Charley’s Fund, Nash Avery Foundation, and Parent Project Muscular Dystrophy, philanthropies seeking cures for DMD.

More information about Tivorsan can be found at www.Tivorsan.com.

Rachel Resnick
Tivorsan Pharmaceuticals, Inc.

Return to News & Information